Summary & Overview
CPT 81541: Prostate Cancer 46‑Gene mRNA Expression Risk Score
CPT code 81541 represents a laboratory molecular diagnostic service that performs mRNA expression profiling of 46 genes and an algorithmic analysis to generate a mortality risk score or estimate risk of recurrence after prostatectomy for patients with a positive prostate cancer biopsy. This code matters nationally as precision oncology tests increasingly guide prognosis and postoperative decision-making, and as payers and laboratories negotiate coverage and clinical utility standards for algorithm‑driven diagnostics. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of clinical context—how the test informs mortality and recurrence risk assessment—plus practical benchmarking and coverage context. The publication summarizes national payer coverage patterns, reimbursement benchmarks where available, and relevant coding and billing considerations for labs and clinician practices. It also outlines the clinical scenario in which the test is used, typical sites of service, and the kinds of results clinicians receive. Data not available in the input are noted where applicable.
Billing Code Overview
CPT code 81541 describes a laboratory service that performs mRNA gene expression profiling for 46 genes and applies an algorithmic analysis combining patient data with lab test results for patients with a positive prostate cancer biopsy. The result reported is a mortality risk score or a prediction of post‑prostatectomy risk of recurrence.
Service type: Laboratory-based molecular diagnostic test with algorithmic/clinical risk modeling
Typical site of service: Clinical laboratory / pathology lab; may be ordered by urology or oncology clinics and performed in a certified molecular diagnostics lab
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 64-year-old man presents after a positive prostate needle core biopsy showing Gleason score 3+4 adenocarcinoma. The urologist and patient are weighing options between active surveillance, radical prostatectomy, or radiation. The clinician orders a molecular prognostic test that measures mRNA expression of 46 genes and applies an algorithm combining tumor gene expression with clinical variables (PSA, Gleason score, tumor stage) to report a mortality risk score and estimate post‑prostatectomy recurrence risk. A commercial molecular laboratory receives the formalin‑fixed paraffin‑embedded biopsy specimen, performs the technical lab processes and gene expression assay, runs the proprietary algorithmic analysis, and issues a report to the ordering provider. Typical site of service is an external clinical molecular diagnostics laboratory with specimen collection performed in an outpatient urology clinic or hospital outpatient setting. Common workflow steps: biopsy in clinic or hospital → specimen accessioning and shipment to reference lab → technical lab testing and QA → algorithmic analysis and report generation → result transmitted to ordering urologist for treatment planning.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When billing only the professional interpretation/analysis portion if separated from technical testing |